arrow
T

Thomas K. Karikari

university of pittsburgh
H指数:63
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Developing the World-Wide FINGERS biorepository for dementia risk reduction trials

开发世界范围内的FINGERS生物样本库以用于痴呆风险降低试验

2026-11-130
OAAI
Loneliness relates to smaller hippocampal subfield volumes in individuals with elevated plasma pTau217: results from IGNITE

孤独感与血浆pTau217升高的个体海马亚区体积较小有关:IGNITE研究的结果

2026-10-230
OAAI
Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

星形胶质细胞反应性识别阿尔茨海默病连续谱中p-tau217阳性个体认知下降的高风险

2026-09-210
OAAI
Spatiotemporal dynamics of tau extent and load increase in Alzheimer’s disease across four longitudinal cohorts

阿尔茨海默病中tau蛋白范围和负荷增加的时空动态变化:基于四项纵向队列研究

2026-07-140
OAAI
Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup

血液和脑脊液生物标志物的2025年前分析指南:NACC ADRC体液生物标志物最佳实践工作组的建议

2026-05-040
OAAI
Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease

简化的资源高效的血浆淀粉样蛋白-β 质谱测定改善了临床前阿尔茨海默氏病的生物标志物性能

2026-01-220
OAAI
Synergistic effects of peripheral inflammation and neuroinflammation on amyloid, vascular, and neurodegeneration markers across the Alzheimer’s disease spectrum

外周炎症和神经炎症对阿尔茨海默病谱系中淀粉样蛋白、血管和神经退行性病变标志物的协同效应

2025-12-230
OA
Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study

血浆生物标志物、脑淀粉样蛋白-β病理学及皮质厚度:一项针对非西班牙裔白人和黑人/非裔美国中年社区队列的研究——HCP-CoBRA研究

2025-12-110
OAAI
Impact of cardiometabolic factors and AD plasma biomarkers on white matter hyperintensities volume in individuals with cognitive complaints from the global south

来自全球南方认知主诉个体的心代谢因素及AD血浆生物标志物对白质高信号体积的影响

2025-12-100
PRE
Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer's disease

血浆可溶性TREM2与有阿尔茨海默病风险的认知正常老年人血浆中的pTau-181和pTau-231相关。

2025-12-090
PRE
Saliva phosphorylated tau concentration is not associated with Alzheimer’s disease; cerebrospinal fluid or blood biomarkers

唾液磷酸化tau浓度与阿尔茨海默病无关联;脑脊液或血液生物标志物

2025-12-020
OAAI
Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease
2025-12-010
OAAI
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

治疗相关淀粉样蛋白清除(TRAC):一种在抗淀粉样蛋白疗法时代用于表征患者的框架

2025-11-260
OAAI
Cross-cohort validation and cutpoint estimation of the Janssen plasma p-tau217+assay in predominantly cognitively normal community studies

跨队列验证和Janssen血浆p-tau217检测的切点估计,在主要认知正常的社区研究中的应用

2025-11-220
OAAI
APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer’s disease

APOE ε4 增强阿尔茨海默病中与tau蛋白相关的反应性星形胶质细胞增生,该增生通过脑脊液YKL40进行评估。

2025-11-200
OA
The Neighborhoods Study: Examining the social exposome in Alzheimer's disease and related dementias

邻里研究:考察阿尔茨海默病及相关痴呆症的社会暴露组

2025-11-130
OAAI
Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults

认知正常老年人脑内Aβ病理的血浆ptau217与ptau217/Aβ1-42分类准确率比较

2025-11-060
PRE
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial

通过急性运动预防阿尔茨海默病理解脑血流动力学(flADex):一项随机交叉试验方案

2025-10-310
OAAI